mms ben dudley

Ben is a seasoned executive with experience gained over a 27-year career in the industry, in both the biopharma and clinical development services sectors. Ben’s deep, broad expertise spans drug development, sales and customer relationship management, operational leadership, and process optimization. He has led truly global teams and diverse delivery portfolios.

Before joining MMS, Ben served as EVP, Head of Global Project Leadership at Parexel, where he was responsible for delivering the full-service clinical project portfolio globally, across biotech and large-pharma segments. Prior roles at Parexel included key sales leadership and strategic partnership positions with large pharma customers. His impressive career also includes leadership roles at Covance and AstraZeneca, where he consistently demonstrated his ability to lead and innovate across various operational, functional, and commercial domains.

The company holds a significant place in the global CRO landscape, and I have witnessed the strength of their expertise over the years. I relish the opportunity to be part of the leadership of an organization with unique capabilities and culture as we continue the next stage of growth and delivery for our customers.
Ben Dudley
Chief Commercial Officer

Ben’s extensive industry experience, particularly in drug development and customer relationship management, equips him with the agility and effectiveness needed to help MMS continue its forward momentum. As CCO, Ben is accountable for all Commercial, Sales and Marketing functions, and strategic growth planning to continually enhance the value of MMS service offerings to our customers and ultimately patients.

Suggested For You

perspectives

October 8th, 2024

Diversity Action Plan Guidance Part I: Implications for Sponsors

webinar

October 22nd, 2024

Optimal Strategies to Protect Commercially Confidential Information (CCI) in Clinical Documents and Report Trial Results Under Revised EU-CTIS Transparency Rules

perspectives

September 30th, 2024

Meet the Leaders Driving MMS’s European Growth

perspectives

September 30th, 2024

The Future of Data Management and Biostatistics: Trends and Technologies Shaping the Industry

perspectives

September 24th, 2024

Embracing Quality Management Maturity (QMM) at the Cornerstone of the Pharmaceutical Industry

perspectives

September 11th, 2024

From Historical Precedent to Modern Approvals: Lessons Learned on OTC Drug Products for FDA OMORs

webinar

September 26th, 2024

Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance

perspectives

September 4th, 2024

Email Security – Navigating Through the Process of Validation and Compliance with Healthcare Business Stakeholders

perspectives

August 27th, 2024

Optimizing Oncology Drug Development: FDA Expedited Pathways, Real-Time Review, and Global Programs

regulatory intelligence

August 27th, 2024

Recent Guidance on Diversity Action Planning

regulatory intelligence

August 26th, 2024

Oncology Programs at the FDA

regulatory intelligence

August 26th, 2024

Three Key Take Reflections on the Recent Donanemab Approval